Compare NTRB & CPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTRB | CPIX |
|---|---|---|
| Founded | 2016 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.0M | 59.5M |
| IPO Year | N/A | 2009 |
| Metric | NTRB | CPIX |
|---|---|---|
| Price | $4.44 | $3.96 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 63.5K | ★ 216.1K |
| Earning Date | 12-11-2025 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $2,278,321.00 | ★ $41,278,349.00 |
| Revenue This Year | $30.17 | N/A |
| Revenue Next Year | $3,394.36 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 12.69 | 12.21 |
| 52 Week Low | $4.17 | $1.85 |
| 52 Week High | $11.78 | $7.25 |
| Indicator | NTRB | CPIX |
|---|---|---|
| Relative Strength Index (RSI) | 49.36 | 45.85 |
| Support Level | $4.25 | $3.84 |
| Resistance Level | $4.74 | $4.92 |
| Average True Range (ATR) | 0.22 | 0.48 |
| MACD | 0.05 | -0.14 |
| Stochastic Oscillator | 71.94 | 7.42 |
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.